β-blockers in the treatment of hypertension: New data, new directions

Journal of Clinical Hypertension

Volumn 10, Issue 3, 2008, Pages 234-238

  Weber, Michael A ^a   Bakris, George L ^b   Giles, Thomas D ^c   Messerli, Franz H ^d  

^a Downstate Health Sciences University   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c TULANE UNIVERSITY   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; ETHANOLAMINE DERIVATIVE; NEBIVOLOL; PROPANOLAMINE DERIVATIVE; VASODILATOR AGENT;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; MIDDLE AGED; MORTALITY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; BENZOPYRANS; CARBAZOLES; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; ETHANOLAMINES; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 43549103550     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.07843.x     Document Type: Note

References (37)

1. Buhler FR, Laragh JH, Baer L, et al. Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive disease. N Engl J Med. 1972;287:1209-1214.
2. The Fourth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC IV). Arch Intern Med. 1988;148:1023-1038.
3. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
4. Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
5. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
6. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med. 2001;134:550-560.
7. Bangalore S, Messerli FH, Kostis JB, et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50(7):563-572.
8. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious aas first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903-1907.
9. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
10. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
12. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
13. Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY Study. Hypertension. 1991;17:579-588.
14. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.
15. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
16. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
17. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203-209.
18. Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther. 2003;8(2):127-134.
19. Williams B, Lacy PS, Thom SM, et al; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAF E Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
20. Packer M, Fowler MB, Roecker EB, et al; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of carvedilol on morbidity of patients witih severe chronic heart failure: results of the carvedilol propective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194-2199.
21. Weber MA, Bakris GL, Tarka EA, et al. Efficacy of a oncedaily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006;8:840-849.
22. Bakris GL, Fonesca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-2236.
23. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet. 2003;362:7-13.
24. Fratta Pasini A, Garbin U, Nava MC, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23(3):589-596.
25. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344-348.
26. Saunders E, Smith WB, DeSalvo KB, et al. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9(11):866-875.
27. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269-277.
28. Stoschitzky K, Stoschitzky G, Brussee H, et al. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology. 2006;106(4):199-206.
29. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-225.
30. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24(3):591-596.
31. Bangalore S, Sawhney S, Uretsky S, et al. Heart rate and antihypertensive therapy: Kjekshus hypothesis revisited [abstract]. Presented at: The American Heart Association Annual Meeting; November 3-7, 2007; Orlando, FL. AHA Scientific Sessions 2007 Presentations. 07-SS-A-13170- AHA.
32. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57(12):43F-49F.
33. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
34. Sipahi I, Tuzcu EM, Wolski KE, et al. Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med. 2007;147(1):10-18.
35. Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst. 2006;7(2):61-63.
36. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task force for the Management of Arterial Hypertension of the European society of Hypertension (ESH) and the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
37. Hypertension AACE Task Force. American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension. Endocr Pract. 2006;12(2):193.